PerkinElmer : to buy Germany's Euroimmun for about $1.3 billion
The deal also offers new infectious disease capabilities to its customers in China, PerkinElmer said.
The acquisition is expected to add about $0.28 to $0.30 per share to PerkinElmer's 2018 adjusted earnings, it said, and reaffirmed its 2017 revenue and earnings per share forecast.
Lubeck, Germany-based Euroimmun, which has about 2,400 employees, is expected to generate about $310 million in revenue this year, PerkinElmer said in a statement.
The deal is expected to close in the fourth quarter of 2017, PerkinElmer said.
(Reporting by Subrat Patnaik in Bengaluru; Editing by Gopakumar Warrier)